Differentiated service delivery models among PLHIV in Akwa Ibom and Cross River States, Nigeria during the COVID-19 pandemic: descriptive analysis of programmatic data.
COVID-19
Nigeria
differentiated service delivery
people living with HIV
treatment retention
viral suppression
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
23
03
2021
accepted:
19
08
2021
entrez:
29
10
2021
pubmed:
30
10
2021
medline:
3
11
2021
Statut:
ppublish
Résumé
The rapid increase in the number of people living with HIV (PLHIV) on antiretroviral therapy (ART) in Akwa Ibom and Cross River states in Nigeria led to overcrowding at clinics. Patients were devolved to receive ART refills through five differentiated service delivery (DSD) models: fast-track (FT), adolescent refill clubs (ARCs), community pharmacy ART refill programs (CPARPs), community ART refill clubs (CARCs) and community ART refill groups (CARGs) designed to meet the needs of different groups of PLHIV. In the context of COVID-19-related travel restrictions, out-of-facility models offered critical mechanisms for continuity of treatment. We compared retention and viral suppression among those devolved to DSD with those who continued standard care at facilities. A retrospective cohort study was conducted among patients devolved to DSD from January 2018 to December 2020. Bivariate analyses were conducted to assess differences in retention and viral suppression by socio-demographic characteristics. Kaplan-Meier assessed retention at 3, 6, 9 and 12 months. Differences in proportions were compared using the chi-square test; a p-value of <0.05 was considered significant. A total of 40,800 PLHIV from 84 facilities received ART through the five models: CARC (53%), FT (19.1%), ARC (12.1%), CPARP (10.4%) and CARG (5.4%). Retention rates at 6 months exceeded 96% for all models compared to 94% among those continuing standard care. Among those using DSD, retention rate at 12 months was higher among adults than children (97.8% vs. 96.7%, p = 0.04). No significant sex differences in retention rates were found among those enrolled in DSD. Viral suppression rates among PLHIV served through DSD were significantly higher among adults than children (95.4% vs. 89.2%; p <0.01). Among adults, 95.4% enrolled in DSD were virally suppressed compared to 91.8% of those in standard care (p <0.01). For children, 89.2% enrolled in DSD were virally suppressed compared to 83.2% in standard care (p <0.01). PLHIV receiving ART through DSD models had retention but higher viral suppression rates compared to those receiving standard care. Expanding DSD during COVID-19 has helped ensure uninterrupted access to ART in Nigeria. Further scale-up is warranted to decongest facilities and improve clinical outcomes.
Identifiants
pubmed: 34713591
doi: 10.1002/jia2.25820
pmc: PMC8554211
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25820Informations de copyright
© 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
Trop Med Int Health. 2015 Apr;20(4):430-47
pubmed: 25583302
J Infect Dis. 2008 Apr 15;197(8):1133-44
pubmed: 18476292
Curr HIV/AIDS Rep. 2019 Aug;16(4):324-334
pubmed: 31230342
Trop Med Int Health. 2010 Jun;15 Suppl 1:1-15
pubmed: 20586956
AIDS Behav. 2021 Feb;25(2):397-413
pubmed: 32812124
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
AIDS. 2016 Sep 10;30(14):2145-8
pubmed: 27367489
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21648
pubmed: 28770597
PLoS One. 2016 Nov 9;11(11):e0165528
pubmed: 27829033
Curr Opin HIV AIDS. 2019 Jan;14(1):60-65
pubmed: 30394947
BMC Infect Dis. 2016 Dec 7;16(1):738
pubmed: 27927183
BMJ Glob Health. 2020 Aug;5(8):
pubmed: 32819917
PLoS One. 2020 Jan 28;15(1):e0228148
pubmed: 31990930
J Int AIDS Soc. 2016 Dec 01;19(1):21484
pubmed: 27914186
J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):540-546
pubmed: 31021988
AIDS. 2021 Feb 2;35(2):299-306
pubmed: 33170578
PLoS One. 2020 Oct 8;15(10):e0238720
pubmed: 33031440
PLoS One. 2014 Mar 20;9(3):e91544
pubmed: 24651523
Niger Postgrad Med J. 2020 Oct-Dec;27(4):271-279
pubmed: 33154278